These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23587174)

  • 21. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
    Darbà J; Kaskens L; Pérez C; Álvarez E; Navarro-Artieda R; Sicras-Mainar A
    Adv Ther; 2014 Jan; 31(1):1-29. PubMed ID: 24390901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
    Álvarez E; Olivares JM; Carrasco JL; López-Gómez V; Rejas J
    Ann Gen Psychiatry; 2015; 14(1):2. PubMed ID: 25632294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial.
    Richards JS; Bombardier CH; Wilson CS; Chiodo AE; Brooks L; Tate DG; Temkin NR; Barber JK; Heinemann AW; McCullumsmith C; Fann JR
    Arch Phys Med Rehabil; 2015 Apr; 96(4):680-9. PubMed ID: 25527253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis.
    Montgomery SA; Mahé V; Haudiquet V; Hackett D
    J Clin Psychopharmacol; 2002 Dec; 22(6):561-7. PubMed ID: 12454555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
    J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.
    Jung J; Tawa EA; Muench C; Rosen AD; Rickels K; Lohoff FW
    Psychiatry Res; 2017 Aug; 254():8-11. PubMed ID: 28437668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
    Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
    J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
    Pande AC; Crockatt JG; Feltner DE; Janney CA; Smith WT; Weisler R; Londborg PD; Bielski RJ; Zimbroff DL; Davidson JR; Liu-Dumaw M
    Am J Psychiatry; 2003 Mar; 160(3):533-40. PubMed ID: 12611835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost effectiveness of pharmacological treatments for generalized anxiety disorder.
    Mavranezouli I; Meader N; Cape J; Kendall T
    Pharmacoeconomics; 2013 Apr; 31(4):317-33. PubMed ID: 23512146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
    Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.